Valuation — not yet established
No valuation for SLAM BioTherapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($9.5M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SLAM BioTherapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Dec 2025 | Seed Round | $1.0M | ▮ | ▮ |
| Feb 2025 | Seed Round | $500K | ▮ | ▮ |
| Nov 2023 | Early Stage VC | $7.7M | ▮ | ▮ |
How SLAM BioTherapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For SLAM BioTherapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has SLAM BioTherapeutics raised?
- SLAM BioTherapeutics has raised $9.5M in total funding across 3 recorded rounds.
- When did SLAM BioTherapeutics last raise?
- SLAM BioTherapeutics last raised in Dec 2025 (Seed Round), raising $1.0M.